Default response to spinal disc injuries can be temporarily stopped to allow for better treatment

Researchers may have found a way to press pause on spinal disc injuries, giving doctors more time to treat them before worse issues develop. The Penn Medicine-led team discovered that cells in the outer region of spinal discs become stressed and kick off a subpar healing process after injuries, which researchers then found can temporarily be blocked with drugs that calm the cells down. This study, conducted using specially engineered biomaterials and small animal models, was published today in Nature Biomedical Engineering.

This work sheds light on some of the challenges we are going to face in slowing disc degeneration and preventing back pain. Most spine research focuses on the inner part of the disc, but our work highlights the fact that we need to treat the whole disc, and we believe doing so may lead to the identification of new targets for therapy."

Edward Bonnevie, PhD, post-doctoral fellow in Penn Medicine's McKay Orthopaedic Research Laboratory

Discs in the spine are pressurized and structured similarly to water balloons, with water-attracting proteins in the inner portion restrained by an outer layer of fibrous tissue containing cells that are under a constant stretch. The discs are designed to cushion the vertebrae from directly and painfully contacting each other. Bonnevie, senior author Robert L. Mauck, PhD, a professor of Orthopaedic Surgery and director of the McKay Lab, and their fellow researchers decided to focus their research on the often overlooked outer region of the discs.

"We know that cells in the inner region undergo changes as a result of disc injury and degeneration, and researchers have tried to restore function to those cells," Bonnevie said. "But you can think of that like trying to fill up a water balloon that already has holes -- it isn't a viable treatment option by itself."

In biomaterials the researchers created to mimic tissue of the outer region of discs, they saw that when an injury like a slipped disc occurs and pressure is lost, the suddenly released tissue becomes disorganized. When this happens, they found in small animal models that it results in the generation of repair tissue that did not resemble the normal tissue, but instead had characteristics of scar tissue.

Additionally, they found that programmed cell death -- known as apoptosis -- occurs quickly, within 24 hours of the injury. This poses a challenge because, unlike other areas in the body, cells in the discs lack a blood supply and cannot easily repopulate with the new cells needed for regeneration.

With the discoveries of why disc cells respond the way they do upon pressure loss, the team found that using a biological inhibitor of cell contraction, such as fasudil, could effectively "relax" the cells from the shock of suddenly losing their typical stretched state. Once relaxed, the cells would delay their default healing response, which has the potential to buy doctors what is called a "therapeutic window" to intervene.

"These data show us that treating disc injuries very soon after injury is essential, before this transition in phenotype occurs and the scar tissue forms. This could be done using inhibitors like fasudil applied systemically, or potentially in combination with surgical implantation of biomaterials that are designed to restore the native tissue structure and function," Mauck explained.

Mauck and other researchers at Penn Medicine are currently exploring such biomaterial-based treatments.

Source:
Journal reference:

Bonnevie, E.D. et al. (2019) Aberrant mechanosensing in injured intervertebral discs as a result of boundary-constraint disruption and residual-strain loss. Nature Biomedical Engineering. doi.org/10.1038/s41551-019-0458-4.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
First U.S. trial uses non-viral CRISPR to correct sickle cell mutation